Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy.
Department of Urology, "F. Miulli" General Hospital, Acquaviva Delle Fonti, Bari, Italy.
World J Urol. 2024 May 20;42(1):338. doi: 10.1007/s00345-024-05043-9.
To compare two cohorts of patients submitted to robot-assisted partial nephrectomy (RAPN) with vs without the use of three-dimensional virtual models (3DVMs).
We screened a prospective consecutive cohort of 152 patients submitted to RAPN with 3DVM and 1264 patients submitted to RAPN without 3DVM between 2019 and 2022. Propensity score matching analysis (PSMA) was applied. Primary endpoint was to evaluate whereas RAPNs with 3DVM were superior in terms of functional outcomes at 12-month. Secondary endopoints were to compare perioperative and oncological outcomes. Multivariable logistic regression analyses (MVA) tested the associations of clinically significant eGFR drop and 3DVMs. Subgroups analysis was performed for PAUDA-risk categories.
100 patients for each group were analyzed after PSMA. RAPN with 3DVM presented a higher rate of selective/no clamping procedure (32% vs 16%, p = 0.03) and a higher enucleation rate (40% vs 29%, p = 0.04). As concern to primary endopoint, 12-month functional preservation performed better within 3DVM group in terms of creatinine serum level (median 1.2 [IQR 1.1-1.4] vs 1.6 [IQR 1.1-1.8], p = 0.03) and eGFR (median 64.6 [IQR 56.2-74.1] vs 52.3 [IQR 49.2-74.1], p = 0.03). However, this result was confirmed only in the PADUA ≥ 10 renal masses. Regarding secondary endpoints, no significative difference emerged between the two cohorts. MVA confirmed 3DVM as a protective factor for clinically significant eGFR drop only in high-risk (PADUA ≥ 10) masses.
RAPN performed with the use of 3DVM assistance resulted in lower incidence of global ischemia and higher rate of enucleations. The positive impact of such technology was found at 12-month only in high-risk renal masses.
比较两组接受机器人辅助部分肾切除术(RAPN)的患者,一组使用三维虚拟模型(3DVM),另一组未使用。
我们筛选了 2019 年至 2022 年期间接受 RAPN 并使用 3DVM 的 152 例患者和未使用 3DVM 的 1264 例患者的前瞻性连续队列。应用倾向评分匹配分析(PSMA)。主要终点是评估使用 3DVM 的 RAPN 在 12 个月时的功能结果是否更优。次要终点是比较围手术期和肿瘤学结果。多变量逻辑回归分析(MVA)测试了临床显著的 eGFR 下降与 3DVM 的关联。对于 PAUDA 风险类别进行了亚组分析。
PSMA 后分析了每组 100 例患者。使用 3DVM 的 RAPN 选择性/无夹闭操作(32%比 16%,p=0.03)和去瘤核操作(40%比 29%,p=0.04)的比例更高。关于主要终点,12 个月时,3DVM 组血清肌酐水平(中位数 1.2[IQR 1.1-1.4]比 1.6[IQR 1.1-1.8],p=0.03)和 eGFR(中位数 64.6[IQR 56.2-74.1]比 52.3[IQR 49.2-74.1],p=0.03)的功能保留更好。然而,这一结果仅在 PAUDA≥10 肾肿瘤中得到确认。关于次要终点,两组之间没有显著差异。MVA 仅在高危(PAUDA≥10)肿瘤中证实 3DVM 是临床显著 eGFR 下降的保护因素。
使用 3DVM 辅助进行 RAPN 可降低整体缺血发生率和去瘤核率。这种技术的积极影响仅在高危肾肿瘤中在 12 个月时显现。